Search Results - "Robins, Deborah A."

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes by Thomas, Melissa K, Nikooienejad, Amir, Bray, Ross, Cui, Xuewei, Wilson, Jonathan, Duffin, Kevin, Milicevic, Zvonko, Haupt, Axel, Robins, Deborah A

“…Abstract Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide…”
Get full text

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes by Hartman, Mark L, Sanyal, Arun J, Loomba, Rohit, Wilson, Jonathan M, Nikooienejad, Amir, Bray, Ross, Karanikas, Chrisanthi A, Duffin, Kevin L, Robins, Deborah A, Haupt, Axel

“…To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of…”
Get full text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens by Frias, Juan Pablo, Nauck, Michael A., Van, Joanna, Benson, Charles, Bray, Ross, Cui, Xuewei, Milicevic, Zvonko, Urva, Shweta, Haupt, Axel, Robins, Deborah A.

“…Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐escalation regimens in patients with type 2 diabetes. Materials…”
Get full text

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis by Loomba, Rohit, Hartman, Mark L., Lawitz, Eric J., Vuppalanchi, Raj, Boursier, Jérôme, Bugianesi, Elisabetta, Yoneda, Masato, Behling, Cynthia, Cummings, Oscar W., Tang, Yuanyuan, Brouwers, Bram, Robins, Deborah A., Nikooie, Amir, Bunck, Mathijs C., Haupt, Axel, Sanyal, Arun J.

“…In this phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than…”
Get full text

A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density by Recker, Robert R., Benson, Charles T., Matsumoto, Toshio, Bolognese, Michael A., Robins, Deborah A., Alam, Jahangir, Chiang, Alan Y, Hu, Leijun, Krege, John H, Sowa, Hideaki, Mitlak, Bruce H., Myers, Stephen L.

“…ABSTRACT Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a…”
Get full text

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes by Wilson, Jonathan M., Nikooienejad, Amir, Robins, Deborah A., Roell, William C., Riesmeyer, Jeffrey S., Haupt, Axel, Duffin, Kevin L., Taskinen, Marja‐Riitta, Ruotolo, Giacomo

“…Aim To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein‐related…”
Get full text

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures by Vuppalanchi, Raj, Loomba, Rohit, Sanyal, Arun J., Nikooie, Amir, Tang, Yuanyuan, Robins, Deborah A., Brouwers, Bram, Hartman, Mark L.

“…Summary Background The use of histological inclusion criteria for clinical trials of at‐risk metabolic dysfunction‐associated steatohepatitis (MASH) is often…”
Get full text

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis by Wilson, Jonathan M., Lin, Yanzhu, Luo, M. Jane, Considine, Gary, Cox, Amy L., Bowsman, Lenden M., Robins, Deborah A., Haupt, Axel, Duffin, Kevin L., Ruotolo, Giacomo

“…In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic polypeptide and…”
Get full text

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist by Benichou, Olivier, Coskun, Tamer, Gonciarz, Malgorzata D., Garhyan, Parag, Adams, Andrew C., Du, Yu, Dunbar, James D., Martin, Jennifer A., Mather, Kieren J., Pickard, Richard T., Reynolds, Vincent L., Robins, Deborah A., Zvada, Simbarashe P., Emmerson, Paul J.

“…GDF15 and its receptor GFRAL/RET form a non-homeostatic system that regulates food intake and body weight in preclinical species. Here, we describe a GDF15…”
Get full text

229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes by ROSENSTOCK, JULIO, ROBINS, DEBORAH A., DUFFIN, KEVIN L., WILSON, JONATHAN M., MATHER, KIEREN J., BANERJEE, HIYA, LIN, YANZHU, EYDE, SARAH, KAZDA, CHRISTOF M., KONIG, MANIGE

“…Orforglipron (OFG), an oral, non-peptide GLP-1 receptor agonist, demonstrated significantly greater glycemic control and weight loss at doses ≥12 mg vs placebo…”
Get full text

336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects by PRATT, EDWARD J., MA, XIAOSU, LIU, RONG, ROBINS, DEBORAH A., SLOOP, KYLE, BENSON, CHARLES

“…Background: LY3502970 (LY) is a novel, highly potent, orally bioavailable nonpeptide GLP-1 receptor agonist (RA) , and a potential alternative to injectable…”
Get full text

333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D) by BENSON, CHARLES, THAM, LAI-SAN, DU, YU, GURBUZ, SIREL, ROBINS, DEBORAH A., MATHER, KIEREN J., TANG, CHENG CAI, THOMAS, MELISSA K.

“…LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple…”
Get full text

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density by Recknor, Christopher P, Recker, Robert R, Benson, Charles T, Robins, Deborah A, Chiang, Alan Y, Alam, Jahangir, Hu, Leijun, Matsumoto, Toshio, Sowa, Hideaki, Sloan, John H, Konrad, Robert J, Mitlak, Bruce H, Sipos, Adrien A

“…ABSTRACT Administration of blosozumab, a humanized monoclonal antibody that binds sclerostin, increases bone formation and bone mineral density (BMD) in…”
Get full text

761-P: Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes by FRIAS, JUAN P., HSIA, STANLEY H., EYDE, SARAH, LIU, RONG, MA, XIAOSU, KONIG, MANIGE, KAZDA, CHRISTOF M., PRATT, EDWARD J., MATHER, KIEREN J., HAUPT, AXEL, ROBINS, DEBORAH A.

“…Orforglipron [OFG (LY3502970)] is an oral, non-peptide, glucagon-like peptide-1 receptor agonist (GLP-1 RA). The 26-week, randomized, double-blind, double…”
Get full text

52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study by WHARTON, SEAN, BLEVINS, THOMAS, CONNERY, LISA B., ROSENSTOCK, JULIO, RAHA, SOHINI, MATHER, KIEREN J., HAUPT, AXEL, ROBINS, DEBORAH A., PRATT, EDWARD J., KAZDA, CHRISTOF M., KONIG, MANIGE

“…Orforglipron (OFG) is a novel once daily oral non-peptide GLP-1 receptor agonist (RA) which can be taken with or without food, in development for chronic…”
Get full text

134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D by HARTMAN, MARK L., SANYAL, ARUN, LOOMBA, ROHIT, WILSON, JONATHAN M., BRAY, ROSS, NIKOOIENEJAD, AMIR, DUFFIN, KEVIN L., ROBINS, DEBORAH A., HAUPT, AXEL

“…Nonalcoholic fatty liver disease (NAFLD) is common in T2D patients and increases the risk of NASH and cirrhosis. In a Phase 2 trial, TZP significantly reduced…”
Get full text

Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes by Wilson, Jonathan M, Lin, Yanzhu, Considine, Gary, Cox, Amy L, Bowsman, Lenden M, Robins, Deborah A, Riesmeyer, Jeffrey S, Haupt, Axel, Duffin, Kevin, Ruotolo, Giacomo

“…IntroductionThe dual GIP/GLP-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with obesity and type 2 diabetes (T2D)…”
Get full text

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis by Wilson, Jonathan M., Lin, Yanzhu, Luo, M. Jane, Considine, Gary, Cox, Amy L., Bowsman, Lenden M., Robins, Deborah A., Haupt, Axel, Duffin, Kevin L., Ruotolo, Giacomo

“…Abstract In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic…”
Get full text

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes by FRIAS, JUAN P., NAUCK, MICHAEL A., VAN, JOANNA, BENSON, CHARLES, BRAY, ROSS, MILICEVIC, ZVONKO, HAUPT, AXEL, ROBINS, DEBORAH A.

“…Initiating incretin hormone receptor agonist therapy at a low dose with gradual dose escalation may improve gastrointestinal (GI) tolerability. This…”
Get full text

980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients by THOMAS, MELISSA K., NIKOOIENEJAD, AMIR, BRAY, ROSS, CUI, XUEWEI, WILSON, JONATHAN M., DUFFIN, KEVIN L., MILICEVIC, ZVONKO, HAUPT, AXEL, ROBINS, DEBORAH A.

“…Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), showed significantly greater glucose control and weight loss compared to the selective…”
Get full text